## Abstract A scaffold‐coating design, the hydroxyapatite (HA) porous bone scaffold coated with poly(ϵ‐)caprolactone (PCL) and HA powder hybrids, was developed for use as tissue‐regeneration and controlled‐release system. An antibiotic drug, tetracycline hydrochloride (TCH), was encapsulated within
Hydroxyapatite/poly(ε-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery
✍ Scribed by Hae-Won Kim; Jonathan C. Knowles; Hyoun-Ee Kim
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 545 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0142-9612
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract To achieve novel polymer/bioceramic composite scaffolds for use in materials for bone tissue engineering, we prepared organic/inorganic hybrid scaffolds composed of biodegradable poly(ε‐caprolactone) (PCL) and hydroxyapatite (HA), which has excellent biocompatibility with hard tissues a
## Abstract The goal of this study was to design a nontoxic scaffold with both composition and microstructure suitable for bone engineering using collagen (Coll), hydroxyapatite (HA), and poly(lactide‐__co__‐ε‐caprolactone) (PLCL). Mineralized type I Coll was produced by direct nucleation of HA par
## Abstract The bioactive hydroxyapatite (HA) coatings were successfully prepared on carbon/carbon composites (C/C) by means of sand‐blasting pretreatment and plasma‐spraying technology. X‐ray diffraction was employed to analyze the phase constitute of the coatings. Meanwhile, the bond strength bet